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Abstract Inhibition of the protease β-site amyloid precursor
protein-cleaving enzyme 1 (BACE1) is a promising treatment
strategy for Alzheimer’s disease, and a number of BACE in-
hibitors are currently progressing through clinical trials. The
strategy aims to decrease production of amyloid-β (Aβ) pep-
tide from the amyloid precursor protein (APP), thus reducing
or preventing Aβ toxicity. Over the last decade, it has become
clear that BACE1 proteolytically cleaves a number of sub-
strates in addition to APP. These substrates are not known to
be involved in the pathogenesis of Alzheimer’s disease but
have other roles in the developing and/or mature central ner-
vous system. Consequently, BACE inhibition and knockout in
mice results in synaptic and other neuronal dysfunctions and
the key substrates responsible for these deficits are still being
elucidated. Of the BACE1 substrates that have been validated
to date, a number may contribute to the synaptic deficits seen
with BACE blockade, including neuregulin 1, close homo-
logue of L1 and seizure-related gene 6. It is important to un-
derstand the impact that BACE blockade may have on these
substrates and other proteins detected in substrate screens and,
if necessary, develop substrate-selective BACE inhibitors.
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Abbreviations
APLP1 Amyloid precursor-like protein 1
APLP2 Amyloid precursor-like protein 2
APP Amyloid precursor protein
Aβ Amyloid β peptide
BACE1 β-Site amyloid precursor protein-cleaving enzyme 1
CHL1 Close homologue of L1
CSF Cerebrospinal fluid
CTF C-terminal fragment
CUB Complement subcomponent C1r/C1s, Uegf, Bmp1




Sez6 Seizure-related gene 6
Sez6L Sez6-like protein
Sez6L2 Sez6-like protein 2
SPECS Secretome protein enrichment with click sugars
BACE1 Is a Therapeutic Target in Alzheimer’s
Disease
Alzheimer’s disease is the most common type of dementia and
is characterised pathologically by amyloid-β (Aβ) plaque de-
position and neurofibrillary tangles. Increased levels of Aβ
peptide produced by proteolytic cleavage of the amyloid pre-
cursor protein (APP) are associated with the formation of
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neurotoxic amyloid aggregates and early synapse loss and
neuronal dysfunction (Shankar et al. 2008; Selkoe and
Hardy 2016). The Aβ peptide is produced by consecutive
cleavage of APP by β- and γ-secretases (Lichtenthaler et al.
2011). Additional APP cleavage products, some of which are
neurotoxic, are generated by α-, δ- and η-secretases
(Lammich et al. 1999; Kuhn et al. 2010; Willem et al. 2015;
Zhang et al. 2015). The β-secretase responsible for the pro-
teolytic processing of APP in the brain is β-site APP-cleaving
enzyme 1 (BACE1) (Vassar et al. 1999). Processing of APP
by BACE1 is the rate-limiting step in the production of Aβ,
and therefore, BACE1 is a major therapeutic target for the
treatment of Alzheimer’s disease.
BACE1 activity increases in the ageing cortex (Fukumoto
et al. 2004), and elevated BACE1 levels can be found in the
brains of Alzheimer’s disease patients (Fukumoto et al. 2002;
Zhao et al. 2007; Hébert et al. 2008). APP mutations in the
human population which increase or decrease APP processing
by BACE1 can promote or protect against the development of
Alzheimer’s disease, respectively (Mullan et al. 1992; Jonsson
et al. 2012). Knockout of BACE1 prevents Aβ production and
improves memory in mouse models of Alzheimer’s disease
(Cai et al. 2001; Luo et al. 2001; Ohno et al. 2004; Ohno et al.
2006; Ohno et al. 2007). Similarly, the administration of com-
petitive inhibitors of BACE1 improves outcomes in animal
models of Alzheimer’s disease and provides the rationale for
extending this treatment to patients (Vassar et al. 2014). A
number of BACE inhibitors are progressing through clinical
trials, the most advanced being MK-8931 from Merck which
is currently in phase III trials (Evin et al. 2015; Barão et al.
2016; Mullard 2016). Results from these and subsequent clin-
ical trials will demonstrate how safe and effective BACE in-
hibitors are for the treatment of Alzheimer’s disease, and may
answer questions regarding the optimal level of BACE inhi-
bition and the utility of this approach for treating patients at
different stages of disease (e.g. prodromal vs. asymptomatic
patients).
However, over the last decade, it has become clear that
BACE1 not only cleaves APP but also has a number of
other proteolytic substrates which are not known to be
involved in the pathogenesis of Alzheimer’s disease but
rather have other roles in the central nervous system.
Concerns have been raised that mechanism-based side ef-
fects of BACE inhibitors may limit their use as therapeutics
(Vassar et al. 2014; Evin et al. 2015; Barão et al. 2016).
Indeed, recent animal studies have shown that BACE inhi-
bition results in synaptic and cognitive deficits (Filser et al.
2015; Willem et al. 2015) and the production of a newly
identified APP peptide, Aη-α, which causes neuronal dys-
function (Willem et al. 2015). Here, we will summarise the
synaptic deficits known to result from BACE1 knockout
and blockade in mice, and describe key BACE1 substrates
that may contribute to this outcome.
Effects of BACE1 Knockout and BACE1 Inhibition
on Synaptic and Neuronal Function
BACE inhibitors are suggested to be most effective when
treatment begins very early in the disease pathogenesis
(Yan and Vassar 2014), and it is therefore important to
know what effect chronic BACE inhibition may have on
the brain in the absence of excess levels of Aβ peptide.
Constitutive BACE1 knockout (KO) mice provide valu-
able information about how BACE1 substrates are affected
when their proteolytic cleavage is altered. BACE1 KO
mice were originally thought to have no significant pheno-
types (Luo et al. 2001), but a number of subtle and more
severe physiological and behavioural deficits have since
been discovered. These include hypomyelination (Hu
et al. 2006; Willem et al. 2006), axon guidance errors in
the olfactory bulb (Rajapaksha et al. 2011; Cao et al. 2012)
and hippocampus (Hitt et al. 2012), seizures (Kobayashi
et al. 2008; Hitt et al. 2010), altered astrogenesis and
neurogenesis (Hu et al. 2013), increased likelihood of post-
natal death and small size (Dominguez et al. 2005), altered
insulin sensitivity (Meakin et al. 2012), decreased anxiety
(Laird et al. 2005), schizophrenia endophenotypes
(Savonenko et al. 2008) and motor deficits (Kobayashi
et al. 2008; Cheret et al. 2013). Notably, BACE1 KO mice
also exhibit alterations in synaptic number and function.
Reduced spine density, including a decreased proportion
of mushroom spines, is seen in CA1 pyramidal neurons
of the BACE1 KO hippocampus (Savonenko et al. 2008).
BACE1 KO mice display altered synaptic plasticity in CA1
and CA3 regions (Laird et al. 2005; Wang et al. 2008;
Wang et al. 2014) which is reflected in deficits in
hippocampal-dependent spatial reference and working
memory (Laird et al. 2005; Kobayashi et al. 2008).
BACE1 KO mice have a complete loss of BACE1, and
while the optimum level of inhibition in patients remains to
be determined, complete inhibition of BACE1 proteolytic
activity is not the aim. Additionally, BACE1 expression is
very high during the first postnatal week in mice (Willem
et al. 2006) and some phenotypes of BACE1 KO mice are
due to altered processing of substrates during develop-
ment. Therefore, they may be of limited relevance to
BACE1 inhibition in the adult brain, even though some
neurodevelopmental processes continue in the adult central
nervous system or may be reactivated in the diseased brain.
Alternatively, it is possible that the lack of BACE1 during
development leads to compensatory changes in constitu-
tive BACE1 KOs, and inhibiting BACE1 in the adult brain
may have more pronounced effects on particular substrates
than predicted from BACE1 KO mice. Fortunately, serious
side effects have not been observed in patients in current
clinical trials but mechanism-based side effects could po-
tentially counteract the benefits of BACE inhibition.
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Recent animal studies indicate that BACE blockade in
adulthood can have a negative effect on neuronal function.
Firstly, BACE inhibition is associated with a reduction in
muscle spindles in adult mice (covered in more detail under
the section ‘Neuregulin 1’) (Cheret et al. 2013). Secondly, a
study by Willem et al. (2015) demonstrates that BACE
inhibitors promote the accumulation of an APP product,
Aη-α, which has a detrimental effect on neuronal function.
The newly discovered η-secretase was found to cleave the
APP protein; this C-terminal fragment (CTF)-η is further
processed by BACE1 or α-secretase to produce Aη-α or
Aη-β peptides, respectively. Inhibiting BACE in mice leads
to increased levels of the Aη-α peptide which is detrimental to
neuronal function, altering long-term potentiation (LTP) and
reducing neuronal activity (Willem et al. 2015). Therefore,
BACE inhibition may simultaneously decrease one neuroto-
xic APP product (Aβ) while increasing another (Aη-α).
Future studies need to clarify whether the increase in Aη-α
seen in mice is also observed in humans. Additionally, it will
be essential to understand whether and how Aη-α contributes
to Alzheimer’s disease. It is currently unclear how the balance
of these two APP peptides will ultimately affect the patholog-
ical and cognitive changes in Alzheimer’s disease patients. In
another recent study, Filser et al. (2015) chronically treated
wild-type mice with a BACE inhibitor and identified altered
synaptic morphology and function and behavioural deficits.
Decreased spine formation on dendrites of cortical pyramidal
neurons was observed, which was reversible upon the
cessation of treatment. BACE inhibition was shown to
decrease neuronal activity and suppress LTP, resulting in
memory deficits as assessed by novel object recognition and
Y maze spontaneous alternation (Filser et al. 2015). The
identification of altered synaptic function and plasticity in
the normal adult mouse brain with BACE blockade is
significant, as BACE inhibitors may work best if patients are
chronically treated from the early stage of the disease. The
synaptic and behavioural changes identified by Filser et al.
were not attributed to specific BACE1 substrates. There are
a number of validated and yet to be validated BACE1
substrates that have known roles in synaptic function and
may contribute to the observed results.
Therefore, it is possible that the BACE inhibitors currently
being trialled will have some detrimental effects on neuronal
function. Inhibition of γ-secretase was previously a viable
therapeutic strategy for Alzheimer’s disease, but phase III
trials were terminated because of adverse side effects which
may have been due to altered processing of the Notch recep-
tor, a γ-secretase substrate (De Strooper 2014). Like BACE1,
γ-secretase cleaves a number of substrates in addition to APP.
While the BACE inhibition strategy is unlikely to have such
severe side effects, there are likely to be mechanism-based
side effects associated with the use of BACE inhibitors.
Important questions remain: what will the short- and long-
term consequences of chronic BACE inhibition be in human
patients? Would the effects of BACE blockade on synapses
still be reversible in humans if treatment were to be continued
for an extended period of time? What is the ideal BACE inhi-
bition strategy which decreases Aβ production while having a
minimal impact on other BACE1 substrates? It is important,
firstly, to identify the main BACE1 substrates associated with
the negative effects on synaptic function and consider whether
the BACE inhibitor strategy could be adapted to allow sparing
of key substrates, if it should prove necessary.
BACE1 Substrates Associated with Synaptic
Function
Dozens of potential proteolytic substrates of BACE1 have
been identified over the last decade, many of which have been
identified through proteomic studies (Hemming et al. 2009;
Kuhn et al. 2012; Zhou et al. 2012; Hogl et al. 2013; Dislich
et al. 2015), and some substrates have been validated in vitro
or in vivo by analysing cleaved substrate products in the ver-
tebrate brain or cerebrospinal fluid (CSF). Of these validated
substrates, several have known roles in synaptic function and
these substrates are discussed below.
Neuregulin 1
Neuregulin 1 (NRG1) is a member of the neuregulin family of
epidermal growth factor (EGF)-like proteins which are ligands
for ErbB tyrosine kinase receptors. NRG1 has multiple isoforms
that arise from alternative splicing, and these are categorised into
six types based on structure (NRG1 types I–VI). All of these
isoforms contain an extracellular EGF-like domain; proteolytic
cleavage of transmembrane NRG1 is required for the release of
the portion of the protein containing this domain, and this solu-
ble form can then bind and activate ErbB receptors (Mei and
Nave 2014). NRG1 has a range of biological functions in the
central and peripheral nervous systems including the regulation
of myelination, radial and tangential neuronal migration (of glu-
tamatergic and GABAergic neurons, respectively) and synaptic
plasticity (Mei and Nave 2014). Thus, inhibition or loss of
BACE1 activity is predicted to alter NRG1-ErbB signalling
and, in fact, a number of the phenotypes seen in BACE1 KO
mice are attributed to the lack of BACE1 cleavage ofNRG1. For
example, BACE1 cleavage of neuronally expressed NRG1 type
III is required for normalmyelination. BACE1KOmice, as well
as zebrafish lacking BACE1, have peripheral hypomyelination
(Hu et al. 2006; Willem et al. 2006; Hu et al. 2008; van Bebber
et al. 2013), and central hypomyelination has also been reported
(Hu et al. 2006). The proteolytic processing of NRG1 type III
and the consequences for myelination have been recently
reviewed (Fleck et al. 2012; Hu et al. 2016) and will not be
described in detail here.
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NRG1-ErbB4 signalling has been intensively studied since
the respective genes encoding these proteins were identified as
schizophrenia susceptibility genes (Stefansson et al. 2002;
Corvin et al. 2004; Mei and Nave 2014; Mostaid et al.
2016). NRG1 heterozygous mice display schizophrenia-like
endophenotypes and impaired hippocampal plasticity
(Stefansson et al. 2002; O’Tuathaigh et al. 2010), and similar
schizophrenia-related endophenotypes are seen in BACE1
KO mice (including impaired pre-pulse inhibition, a greater
level of hyperactivity induced by a glutamatergic
psychostimulant, cognitive impairments and social recogni-
tion deficits; Savonenko et al. 2008). A reduction in PSD-
95-associated ErbB4 was also observed in these BACE1 KO
mice, supporting the idea that the lack of BACE1 processing
of NRG1 and subsequent impairment of NRG1-ErbB4 signal-
ling contributed to the phenotypes observed (Savonenko et al.
2008). Taken together, there is strong evidence from NRG1
overexpression and knockout studies in mice (Mostaid et al.
2016) for the association of altered developmental NRG1-
ErbB4 signalling with schizophrenia; however, relatively
few studies have addressed the role of BACE1-cleaved
NRG1 in the mature brain.
The persistence of NRG1 and ErbB4 expression in the
adult central nervous system, including in neurons of the cor-
tex and hippocampus, indicates ongoing roles for NRG1
signalling in maturity (Mei and Xiong 2008). NRG1-ErbB4
signalling is important in regulating synaptic function at both
excitatory and inhibitory synapses. For example, ErbB4 is
recruited in an activity-dependent manner to the postsynaptic
compartment of hippocampal CA1 excitatory synapses where
it is activated by soluble NRG1. Binding of NRG1 enhances
ErbB4 association with PSD-95 in the postsynaptic scaffold,
strengthening glutamatergic synapses through stabilising
synaptic AMPA receptors and maintaining dendritic spine
synapses (Li et al. 2007). While loss of NRG1-ErbB4 signal-
ling is detrimental (Li et al. 2007; Agarwal et al. 2014),
excessive NRG1-ErbB4 activity (as seen in schizophrenia) is
also associated with synaptic dysfunction resulting from
suppression of LTP-induced NMDA receptor function
(Pitcher et al. 2011; Agarwal et al. 2014; Luo et al. 2014).
ErbB4 is also expressed in interneurons in the postnatal
and adult brains and is required presynaptically in cortical
GABAergic axon terminals for the formation of inhibitory
synapses onto pyramidal neurons (Mei and Nave 2014).
In dendrites of interneurons, ErbB4 acts postsynaptically
at excitatory synapses (Fazzari et al. 2010). Interestingly,
deletion of ErbB4 only in fast-spiking interneurons
produced neurophysiological and behavioural deficits
consistent with schizophrenia endophenotypes (Del Pino
et al. 2013). Thus, NRG1 function must be precisely
regulated to maintain normal glutamatergic receptor
functions at synapses and balanced excitatory-inhibitory
neurotransmission in the cortex.
Another important ongoing role of BACE1-processed
NRG1 and NRG1-ErbB signalling is the maintenance of
muscle spindles, sensory receptors that detect changes in
muscle length (Cheret et al. 2013). Chronic treatment of adult
wild-type mice with a BACE inhibitor led to a substantial loss
of spindles and consequent impairment in motor co-ordination
(Cheret et al. 2013). Careful assessment of motor function in
patients during chronic BACE inhibitor treatment will be
necessary to monitor this potential side effect.
Sez6 Family
The seizure-related gene 6 (Sez6; also referred to as Seizure 6,
Seizure protein 6 and BSRP) family of proteins includes Sez6,
Sez6-like (Sez6L) and Sez6-like 2 (Sez6L2). All three family
members were identified as BACE1 substrates from a screen
that identified proteins shed from cultured neurons using the
secretome protein enrichment with click sugars (SPECS) meth-
od (Kuhn et al. 2012). Sez6 was validated as a BACE1 sub-
strate, and Sez6 and Sez6L were found to be cleaved predom-
inantly or exclusively by BACE1 (Kuhn et al. 2012). Sez6 is a
prime candidate for involvement in the synaptic dysfunction
seen with BACE inhibition (Filser et al. 2015) as it is expressed
in the adult brain and has known roles in dendrite and spine
development (Gunnersen et al. 2007). Given the growing inter-
est in Sez6 family proteins as BACE1 substrates, we have pro-
vided a comprehensive coverage of the literature below.
Sez6 messenger RNA (mRNA) is upregulated by neuronal
activity (Shimizu-Nishikawa et al. 1995b) and predominantly
localised to the central nervous system (Shimizu-Nishikawa
et al. 1995b; Herbst and Nicklin 1997). High levels of Sez6
protein are found in the developing and postnatal forebrain
(Kim et al. 2002; Gunnersen et al. 2007; Osaki et al. 2011),
with Sez6 being detected in the somatodendritic compartment
of neurons (Miyazaki et al. 2006; Gunnersen et al. 2007). Sez6
mRNA and protein expression remains relatively high in re-
gions of the adult mouse central nervous system including the
cortex, hippocampus, striatum, olfactory tubercule (Herbst
and Nicklin 1997; Miyazaki et al. 2006; Gunnersen et al.
2007; Osaki et al. 2011), retina (Gunnersen et al. 2009) and
spinal cord (BGraham and J Gunnersen, unpublished data). In
constitutive Sez6 KO mice, neurons exhibit morphological
alterations including an increased number of dendrites and
fewer spines (Gunnersen et al. 2007). Both BACE1 KO and
Sez6 KO mice have reduced dendritic spine densities
(Savonenko et al. 2008; Gunnersen et al. 2007), deficits in
hippocampal-dependent learning (Laird et al. 2005;
Gunnersen et al. 2007) and motor deficits (Kobayashi et al.
2008; Gunnersen et al. 2007). The Sez6 gene is highly con-
served between mice and humans, and sez6 mutations and/or
altered expression has been associated with febrile seizures
(Yu et al. 2007; Mulley et al. 2011), autism spectrum disorder
(Cukier et al. 2014; Mariani et al. 2015), intellectual disability
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(Gilissen et al. 2014) and childhood-onset schizophrenia
(Ambalavanan et al. 2016). Elevated, or decreased, levels of
Sez6 in the CSF are observed in adult patients with psychiatric
disorders (Maccarrone et al. 2013) and Alzheimer’s disease
(Khoonsari et al. 2016), respectively.
Sez6 family proteins are each represented by multiple
isoforms. Full-length type I transmembrane protein iso-
forms consist of a signal sequence, a large extracellular
or luminal region containing complement subcomponent
C1r/C1s, Uegf, Bmp1 (CUB) domains and sushi (also
known as short consensus repeat [SCR] or complement
control protein [CCP]) domains, a transmembrane region
and a short intracellular region containing an NPxY mo-
tif, potential phosphorylation sites (Shimizu-Nishikawa
et al. 1995b; Miyazaki et al. 2006) and a potential
PDZ protein binding domain at the C-terminus (J
Gunnersen, unpublished). The presence of CUB and
sushi domains suggests that Sez6 family proteins inter-
act with other central nervous system proteins, and an
interaction between Sez6 and the protease neurotrypsin
(also known as motopsin) has been reported (Mitsui
et al. 2013). From the single sez6 gene, two different
transmembrane protein isoforms and a truncated isoform
lacking the transmembrane region (secreted) are gener-
ated via alternative splicing of the sez6 mRNA
(Shimizu-Nishikawa et al. 1995a; Miyazaki et al.
2006). Sez6 transmembrane and secreted isoforms have
opposing actions on dendritic outgrowth in vitro
(Gunnersen et al. 2007). Overexpression of the full-
length transmembrane Sez6 in neurons lacking endoge-
nous Sez6 inhibits neurite outgrowth while secreted
Sez6 promotes it. BACE1 cleaves the transmembrane
form of Sez6 to produce a shed ectodomain that is sim-
ilar to (although larger than) the secreted Sez6 isoform
(Kuhn et al. 2012). It will be important to determine
whether the BACE1-shed Sez6 ectodomain performs a
similar functional role to the secreted isoform, as
effective BACE inhibition would be expected to block
ectodomain shedding while enhancing the levels of the
intact transmembrane form, as shown in mice (Kuhn
et al. 2012).
Like Sez6, Sez6L and Sez6L2 are localised to the
somatodendritic compartment of neurons (Miyazaki et al.
2006). Sez6L and Sez6L2 mRNA is found throughout the
adult mouse brain in regions including the cortex, hippocam-
pus and olfactory bulb (Miyazaki et al. 2006).Mice lacking all
Sez6 family members (triple KOmice) have significant motor
co-ordination deficits attributed to abnormal climbing fibre
innervation in the cerebellum; loss of Sez6L appears to be
mostly responsible for this phenotype. The lack of reported
phenotypes in the single KO mouse lines in this study indi-
cates a level of functional redundancy between Sez6 family
members (Miyazaki et al. 2006). Nevertheless, knockdown of
individual Sez6 family members results in decreased calcium
spiking frequency and amplitude in cultured neurons
(Anderson et al. 2012).
Sez6L was also identified by Kuhn et al. (2012) as a BACE
substrate using SPECS. Although not yet validated by other
means, further investigation is warranted as, like Sez6, it is
predominantly cleaved by BACE1 rather than other proteases
(Kuhn et al. 2012). Little is known about its neuronal function
although Sez6L mRNA is widely expressed in the adult brain
in regions including the cortex and hippocampus (Miyazaki
et al. 2006). Sez6L is linked to bipolar disorder (Xu et al.
2013). Outside the central nervous system, sez6L genetic var-
iants are associated with multiple cancer types, inflammation
and cardiovascular disease. Sez6L2 has been linked to autism
(Kumar et al. 2009; Konyukh et al. 2011; Chapman et al.
2015) and is likely to play an important role in central nervous
system development. Levels of the shed Sez6L2 ectodomain
are decreased in the CSF of BACE1 KO mice (Dislich et al.
2015), although Sez6L2 is likely to be cleaved by other pro-
teases in addition to BACE1 (Kuhn et al. 2012) and cathepsin
D is one such protease (Boonen et al. 2016). In this report,
Sez6L2 was identified as a transport receptor for cathepsin D,
an aspartyl protease found in lysosomes, and was localised to
endosomes, the trans-Golgi network and the plasma mem-
brane. Similarly to Sez6, full-length and proteolytically
cleaved Sez6L2 exhibited opposing effects on neuronal diffe-
rentiation and neurite outgrowth in neuroblastoma cells
(Boonen et al. 2016). Sez6L and Sez6L2 are expressed in
the pancreas where they are BACE2 but not BACE1 sub-
strates, demonstrating the tissue-specific cleavage of these
proteins. The CTFs of BACE2-cleaved Sez6L and Sez6L2
are subsequently cleaved by γ-secretase (Stützer et al.
2013), raising the possibility that Sez6 family proteins may
undergo this secondary cleavage in the central nervous
system.
To understand how Sez6 family proteins contribute to the
synaptic deficits seen with BACE inhibition, we need to
investigate more fully the functions of uncleaved Sez6 and
the BACE1-cleaved Sez6 ectodomain, and learn more about
the roles of Sez6L and Sez6L2 in the adult central nervous
system.
CHL1 and L1
L1 (also called L1 cell adhesion molecule) and close homo-
logue of L1 (CHL1) are members of the L1 family of cell
adhesion molecules and part of the immunoglobulin super-
family. CHL1 and L1 are type I transmembrane proteins
which are widely expressed in neurons, particularly in the
developing central nervous system where they facilitate
neurite outgrowth, axonal targeting and cell migration
(Hillenbrand et al. 1999; Maness and Schachner 2007).
CHL1 and L1 cleavage by ADAM proteases alters their
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function, likely through the release of extracellular fragments
or reduction of cell adhesion (Maness and Schachner 2007).
CHL1 and L1 were identified as neuronal BACE1 substrates
through proteomic screening (Kuhn et al. 2012; Zhou et al.
2012), and they have been validated as physiological BACE1
substrates in vivo (Hitt et al. 2012; Kuhn et al. 2012; Zhou
et al. 2012; Dislich et al. 2015).
Neuronal CHL1 is enriched in the axonal membrane
(Leshchyns’ka et al. 2006), and co-localisation with BACE1
is observed in growth cones in vitro and pre-synaptic termi-
nals in the postnatal mouse brain (Hitt et al. 2012). Similar
hippocampal mossy fibre and olfactory sensory neuron axon
guidance defects are observed in constitutive CHL1 KO
(Montag-Sallaz et al. 2002) and BACE1 KO mice
(Rajapaksha et al. 2011; Cao et al. 2012; Hitt et al. 2012),
suggesting that BACE1 processing of CHL1 is required for
normal axon targeting. BACE1 cleavage of CHL1 has been
shown to contribute to growth cone collapse through interac-
tions of the CHL1-CTF with the axonal guidance molecule
semaphorin 3A (Barão et al. 2015).
CHL1 expression decreases following development but
persists in the mature central nervous system (Hillenbrand
et al. 1999), indicating an ongoing function of CHL1 in the
adult brain. CHL1 has a demonstrated role in synaptic trans-
mission: CHL1 accumulates in the pre-synaptic membrane
and, through an association of the CHL1 intracellular domain
with the chaperone Hsc70, regulates the uncoating of clathrin-
coated synaptic vesicles (Leshchyns’ka et al. 2006).
Conditional KO mice, in which CHL1 was ablated in excit-
atory forebrain neurons following postnatal development, ex-
hibited an impaired working memory duration (Kolata et al.
2008) indicating a role for CHL1 in this process in the mature
brain. Similarly, L1 is expressed in neurons of the adult brain
including the cerebral cortex and hippocampus (Hillenbrand
et al. 1999; Horinouchi et al. 2005). Conditional KO mice in
which L1 is deleted in mature excitatory forebrain neurons do
not display the severe developmental abnormalities seen in
constitutive L1 KO mice (Maness and Schachner 2007).
However, conditional L1 KO mice display increased basal
excitatory activity in hippocampal CA1 and use different
search strategies in the Morris water maze, indicating an
alteration in place learning (Law et al. 2003).
APP Family
The APP peptide Aη-α, while not a BACE1 product, is
detrimental to neuronal function and is increased in the pre-
sence of BACE inhibitors as discussed previously (Willem
et al. 2015). Full-length APP and its peptide products also
have non-toxic physiological roles related to cell adhesion,
intracellular signalling, synaptic function and more, reviewed
in detail elsewhere (Müller and Zheng 2012; Nhan et al.
2015). Cleavage of APP by α-secretase or BACE1 leads to
the release of soluble ectodomains APPsα and APPsβ,
respectively. APPsα has synaptotropic and neuroprotective
properties; however, APPsβ has not been shown to have the
same potent effect on synapses (Hick et al. 2015; Nhan et al.
2015). The cytoplasmic domain of APP also has a demonstra-
ted role in normal synaptic function (Klevanski et al. 2015).
Within the same gene family are amyloid precursor-like pro-
tein 1 (APLP1) and amyloid precursor-like protein 2
(APLP2), expressed in the adult brain (Lorent et al. 1995).
APLP1 and APLP2 are also type I transmembrane proteins
that undergo cleavage by secretases, including BACE1
(Eggert et al. 2004; Li and Südhof 2004; Hogl et al. 2011),
to produce a soluble ectodomain, intracellular domain and
other (non-Aβ) peptide fragments. Neuronal APLP1 is almost
exclusively cleaved by BACE1 (Kuhn et al. 2012); however,
relatively little is known about its function. Constitutive
APLP1 KO mice display altered synaptic transmission in the
dentate gyrus, but to date, there is no clear role for APLP1 in
synaptic plasticity (Vnencak et al. 2015). Further study is
needed to determine how BACE processing affects APLP1
function.
Additional BACE1 Substrates
Other potential BACE1 substrates with known roles in synap-
tic function have been identified in proteolytic screens but
await validation in vitro or in vivo. For example, neuroligin
1α, neuroligin 2, neuroligin 4 and neurexin 1α, well-known
synaptic cell adhesion molecules, have been identified as like-
ly neuronal BACE1 substrates (Kuhn et al. 2012; Bemben
et al. 2015). BACE1 substrates also include proteins that
influence the excitability of neurons, including the β-
subunits of voltage-gated sodium channels (Wong et al.
2005; Kim et al. 2007; Gersbacher et al. 2010) and subunits
of voltage-gated potassium channel proteins, KCNE1 and
KCNE2 (Sachse et al. 2013). The BACE1 substrate
contactin-2 (Kuhn et al. 2012; Zhou et al. 2012) is a cell
adhesion molecule that, together with CASPR2, maintains
voltage-gated potassium channels at juxtaparanodal regions
of myelinated axons (Poliak et al. 2003). Additionally, while
BACE1 primarily acts as a protease, BACE1 can interact non-
proteolytically with voltage-dependent sodium channels
(Huth et al. 2009) and KCNQ potassium channels (Hessler
et al. 2015). Therefore, BACE blockade may alter neuronal
excitability through multiple mechanisms.
Neuronal Localisation of BACE1
Identifying the subcellular compartments in which BACE1
interacts with APP and its additional substrates may promote
the development of BACE inhibitors that are ‘substrate
310 J Mol Neurosci (2016) 60:305–315
sparing’, if adverse mechanism-based side effects of this
treatment are found.
BACE1 is expressed in neurons in multiple areas of the
healthy and diseased adult brain, including the cortex and
hippocampus (Vassar et al. 1999; Fukumoto et al. 2002). In
human and mouse neurons, BACE1 is detected in the axonal
and somatodendritic compartments; in mouse neurons,
BACE1 is transported to, and enriched in, axons (Buggia-
Prévot et al. 2013; Buggia-Prévot et al. 2014). BACE1 is
prominent in pre-synaptic terminals, and levels are high in
the terminals of dystrophic neurites surrounding Aβ plaques
(Laird et al. 2005; Zhao et al. 2007; Kandalepas et al. 2013;
Sadleir et al. 2016).
BACE1 activity is greatest at acidic pH and can be
indirectly inhibited with drugs, such as bepridil, which
alkalize the membrane-proximal areas of acidic organelles
(Mitterreiter et al. 2010). A recent study by Das et al. (2016)
determined that the main subcellular interaction sites of
BACE1 and APP in cultured hippocampal neurons depend
on the neuronal compartment. In dendrites, including dendri-
tic spines, interaction is most frequent in recycling endosomes
with fewer interactions occurring in early endosomal, lyso-
somal and Golgi vesicles. In axons, the majority of BACE1-
APP interactions occur in Golgi-derived vesicles (Das et al.
2016). Validated BACE1 substrates have varied subcellular
locations. For example CHL1, L1 and contactin-2 are
enriched in axons while Sez6 is localised to the
somatodendritic compartment (Gunnersen et al. 2007). Sez6
has been shown to be internalised from the surface of cultured
neurons and to be present in transferrin receptor (TfR)-posi-
tive early/recycling endosomes (Carrodus et al. 2014); how-
ever, further experiments are required to determine whether
this compartment is the site of the BACE1-Sez6 interaction.
Identification of the BACE1 substrates that are required for
normal synaptic function in the mature brain and elucidation
of their subcellular locations will help determine strategies to
modify the BACE inhibition approach, if required. For
example, experimental approaches to decrease Aβ production
while minimising the blockade of key BACE1 substrates in-
clude altering the trafficking of BACE1 (Kizuka et al. 2015)
and using an endosomally targeted BACE inhibitor (Ben
Halima et al. 2016). However, it is possible that the latter
strategy will not spare all substrates, as Sez6 family proteins
are also abundant in endosomes (Miyazaki et al. 2006;
Carrodus et al. 2014).
Summary
BACE inhibitors for the treatment of Alzheimer’s disease are
progressing through clinical trials. If this strategy is found to
be effective in preventing or reducing cognitive decline in
Alzheimer’s disease patients, considerations for the use of
BACE inhibitors include identifying the stage at which the
treatment should begin, determining the ideal levels of
BACE inhibition at different disease stages and investigating
the benefit of combining BACE inhibitors with additional
therapeutic strategies. Furthermore, a level of caution
surrounds the BACE inhibitor strategy as BACE1 has a num-
ber of other substrates in addition to APP. It is imperative that
we understand the effects of altered BACE1 cleavage of key
substrates and, if warranted, aim to adapt the BACE inhibitor
strategy tominimisemechanism-based side effects. Therefore,
gaining a better understanding of the fundamental roles of
BACE1 substrates in the adult brain and how (and in which
subcellular compartments) BACE1 cleavage modulates these
functions is of the utmost importance.
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